Annals of Surgical Oncology

, Volume 23, Issue 3, pp 715–721 | Cite as

Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome

  • Julian Johnson
  • Laura Esserman
  • Cheryl Ewing
  • Michael Alvarado
  • Catherine Park
  • Barbara FowbleEmail author
Breast Oncology


Background and Objectives

Invasive chest wall recurrences (CWR) following mastectomy are typically treated with surgical excision, radiation therapy (RT) to the chest wall and supraclavicular (SCV) region, and appropriate systemic therapy. Repeat axillary surgery is not routinely performed if the axilla is clinically negative. We evaluated sentinel node biopsy (SNB) in patients with an isolated invasive CWR, for identification and biopsy rates, non-axillary drainage, and clinical implications for radiation fields and outcome.


Between 2008 and 2013, 12/19 women with an isolated invasive CWR had sentinel node (SN) mapping with Tc99m. Median age was 53 years, and 92 % (11/12) had initial path N0 disease. All had prior SNB, with axillary dissection in one patient.


Overall, 83 % (10/12) had successful mapping, with 70 % (7/10) having an axillary SN. Ninety percent (9/10) had successful axillary node biopsy, with one patient having positive nodes. SCV RT was omitted in those with negative axillary nodes. With a median follow-up of 4.6 years from recurrence, there have been no SCV recurrences and no instances of lymphedema.


SNB is possible in women with an isolated CWR with acceptable identification and biopsy rates. Omission of routine irradiation of the SCV region has not jeopardized regional control and results in decreased morbidity.


Sentinel Node Sentinel Node Biopsy Lymphedema Axillary Dissection Sentinel Node Mapping 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Morris AD, Morris RD, Wilson JF, White J, et al. Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J Sci Am. 1997;3(1):6-12PubMedGoogle Scholar
  2. 2.
    Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150(1):9-16CrossRefPubMedGoogle Scholar
  3. 3.
    Jagsi R, Jiang J, Momoh AO, et al. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol. 2014;32(9):919-926CrossRefPubMedGoogle Scholar
  4. 4.
    Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10): 927-33PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251(4): 595-600,CrossRefPubMedGoogle Scholar
  6. 6.
    Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106: 4-16CrossRefPubMedGoogle Scholar
  7. 7.
    Halverson KJ, Perez CA, Kuske RR, et al. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys. 1990;19:851-858CrossRefPubMedGoogle Scholar
  8. 8.
    Schwaibold F, Fowble BL, Solin LJ, et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys. 1991;21(2):299-310.CrossRefPubMedGoogle Scholar
  9. 9.
    Kim M, Kim SW, Lee SU, et al. A model to estimate the risk of breast cancer-related lymphedema: combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(3):498-503.CrossRefPubMedGoogle Scholar
  10. 10.
    Hayes SB, Freedman GM, Li T, et al. Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation? Int J Radiat Oncol Biol Phys. 2008;72(5)1449-55.CrossRefPubMedGoogle Scholar
  11. 11.
    Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1992;23(5):915-23.CrossRefPubMedGoogle Scholar
  12. 12.
    Burstein HJ, Bellon JR, Galper S, et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006;64(2):496-504.CrossRefPubMedGoogle Scholar
  13. 13.
    Lind PA, Marks LB, Hardenbergh PH, et al. Technical factors associated with radiation pneumonitis after local ± regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52(1):137-43.CrossRefPubMedGoogle Scholar
  14. 14.
    Matzinger O, Heimsoth I, Poortmans P, et al. EORTC Radiation Oncology and Breast Cancer Groups. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). Acta Oncol. 2010;49(1):24-34.CrossRefPubMedGoogle Scholar
  15. 15.
    Chapgar A, Kuerer HM, Hunt KK, et al. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 2003;57(1):128-35CrossRefGoogle Scholar
  16. 16.
    Maaskant-Braat AJ, Voogd AC, Roumen RM, et al. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2013;138(1):13-20CrossRefPubMedGoogle Scholar
  17. 17.
    Aebi S, Gelber S, Anderson SJ, et al.; CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomized trial. Lancet Oncol. 2014;15(2):156-63PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Maaskant-Braat AJ, Roumen RM, Voogd AC, et al. Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study. Ann Surg Oncol. 2013;20(2):620-6CrossRefPubMedGoogle Scholar
  19. 19.
    Uth CC, Christensen MH, Oldenbourg MH, et al. Sentinel lymph node dissection in locally recurrent breast cancer. Ann Surg Oncol. 2015;22(8):2526–31CrossRefPubMedGoogle Scholar
  20. 20.
    Karam A, Stempel M, Cody HS, et al. Reoperative sentinel lymph node biopsy after previous mastectomy. J Am Coll Surg. 2008;207(4): 543-548CrossRefPubMedGoogle Scholar
  21. 21.
    Boughey JC, Ross MI, Babiera GV, et al. Sentinel lymph node surgery in locally recurrent breast cancer. Clin Breast Cancer. 2006;7(3):248-53.CrossRefPubMedGoogle Scholar
  22. 22.
    Intra M, Veronesi P, Gentilini OD, et al. Sentinel lymph node biopsy is feasible even after total mastectomy. J Surg Oncol. 2007;95(2):175-9.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Julian Johnson
    • 1
  • Laura Esserman
    • 2
  • Cheryl Ewing
    • 2
  • Michael Alvarado
    • 2
  • Catherine Park
    • 1
  • Barbara Fowble
    • 1
    Email author
  1. 1.Department of Radiation OncologyUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Department of SurgeryUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations